Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose The aim of this study was to evaluate the therapeutic effects of Anamorelin on patients with cancer anorexia-cachexia syndrome (CACS) based on a meta-analysis of published randomized trials.Methods We searched PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases. Data from each selected study were evaluated individually. All continuous outcomes were calculated by the mean difference or standardized mean difference with 95% confidence interval for each study. Heterogeneity was assessed by using the Chi 2 test at a significance level of P < 0.1, in addition to the I 2 statistic (I 2 > 50% indicated substantial heterogeneity).Result At last, four studies were included from 284 records. In three studies, lean body mass was reported and there was a significant difference between placebo and Anamorelin groups (P < 0.00001), without significant heterogeneity (I 2 = 0%). All the four studies reported the body weight change from baseline, and there was significant difference between placebo and Anamorelin groups (P = 0.007), but with high heterogeneity (I 2 = 97%). Two studies reported Anderson Symptom Assessment Scale (ASAS) score, and Anamorelin significantly increased the total ASAS score of CACS patients (P < 0.00001), without any heterogeneity (I 2 = 0%). Three studies reported non-dominant handgrip strength, and there was no significant difference between Anamorelin and placebo groups (P = 0.16). Three studies reported insulin-like growth factor-1 level, and there was significant difference between Anamorelin and placebo groups (P = 0.02), but with high heterogeneity (I 2 = 96%). Three studies reported IGF binding protein-3 concentration. Anamorelin significantly increased such concentration compared with placebo did (P < 0.00001). However, there was still higher heterogeneity (I 2 = 59%). All the included studies reported adverse events. Compared with placebo, Anamorelin induced fewer adverse events, but there was no significant difference between the two groups (RR = 0.07, P = 0.35).Conclusion In the included studies, Anamorelin had some positive effects to relieve the symptoms and improved the quality of life. However, the heterogeneity was apparent, so the clinical effects of Anamorelin should be further validated by increasing the sample size, varying the range of doses during treatment, and observing other outcomes. We are still confident for the future application of Anamorelin in phase III clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A review of four studies demonstrated high heterogeneity with improved symptom scores, and in three studies, improved lean mass was shown439.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [439]
Citations
Cites
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review
Teunissen, S. C. C. M., Wesker, W., Kruitwagen, C., de Haes, H. C. J. M., Voest, E. E., & de Graeff, A. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.015 · Cited by 990
Ghrelin Strongly Stimulates Growth Hormone Release in Humans
Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7167 · Cited by 864
Grip strength, body composition, and mortality
Gale, C. R., Martyn, C. N., Cooper, C., & Sayer, A. A. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dyl224 · Cited by 737
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management
Inui, A. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.2.72 · Cited by 579
Cachexia as a major underestimated and unmet medical need: facts and numbers
von Haehling, S., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0002-6 · Cited by 533
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Ross, P. J., Ashley, S., Norton, A., Priest, K., Waters, J. S., Eisen, T., Smith, I. E., & O'Brien, M. E. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601781 · Cited by 476
Aapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S. M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu085 · Cited by 308
Research works printed but not linked: 1
- Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88:2164–2171 · doi:10.1002/(sici)1097-0142(20000501)88:9<2164::aid-cncr24>3.0.co;2-5
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Inter-tissue communication in cancer cachexia
Argilés, J. M., Stemmler, B., López-Soriano, F. J., & Busquets, S. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0123-0 · Cited by 305
Advani, S., Advani, P. G., VonVille, H. M., & Jafri, S. H. R. (2018) · BMC Cancer · doi:10.1186/s12885-018-5080-4 · Cited by 140
Gea, J., Sancho‐Muñoz, A., & Chalela, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.66 · Cited by 126
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment
Hariyanto, T. I., & Kurniawan, A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100336 · Cited by 101
Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management
Siff, T. E., Parajuli, P., Razzaque, M. S., & Atfi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.007 · Cited by 77
Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia
Sakuma, K., & Yamaguchi, A. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2077-9 · Cited by 63
Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.
Schcolnik‐Cabrera, A., Chávez-Blanco, A. D., Domínguez-Gómez, G., & Dueñas‐González, A. (2017) · Europe PMC (PubMed Central) · Cited by 76
The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews
Zhang, F., Shen, A., Jin, Y., & Qiang, W. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2304-8 · Cited by 55
Fidler, M. J., Fhied, C. L., Roder, J., Basu, S., Sayidine, S., Fughhi, I., Pool, M. D., Batus, M., Bonomi, P., & Borgia, J. A. (2018) · BMC Cancer · doi:10.1186/s12885-018-4193-0 · Cited by 43
Ghrelin for the management of cachexia associated with cancer
Khatib, M. N., Shankar, A. H., Kirubakaran, R., Gaidhane, A. M., Gaidhane, S., Simkhada, P. P., & Zahiruddin, Q. S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012229.pub2 · Cited by 54
Taniguchi, J., Mikura, S., & Lopes, K. D. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-42446-x · Cited by 37
Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review
Naito, T. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s196802 · Cited by 38
Pancreatic cancer: Best supportive care
Védié, A., & Neuzillet, C. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.02.032 · Cited by 36
Invernizzi, M., Alessandro de, S. I. R. E., & Fusco, N. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.003 · Cited by 27
Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis
Liu, H., Lü, L., Zou, J., Zhou, T., Wang, B., Sun, H., & Yu, S. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2684-4 · Cited by 27
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
Rivas, A. S., Escobar, Y., Blasco, A., Tarruella, M. M., Mata, K. M., de la Cámara, M. M., Muñoz-Sánchez, M. M., Poves, M. Z., Zambrano, C. B., & Gutiérrez, L. C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03502-8 · Cited by 33
Derksen, J. W. G., Kurk, S. A., Oskam, M. J., Peeters, P. H. M., Punt, C. J. A., Koopman, M., & May, A. M. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz016 · Cited by 26
Miyake, M., Hori, S., Itami, Y., Oda, Y., Owari, T., Fujii, T., Ohnishi, S., Morizawa, Y., Gotoh, D., Nakai, Y., et al. (2020) · Cancers · doi:10.3390/cancers12071942 · Cited by 23
Borba, V. Z. C., & Costa, T. M. D. R. L. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0084 · Cited by 21
Updates in Cancer-Related Symptom Management of Anorexia and Cachexia Syndrome
Oakvik, J., & Ready, D. (2022) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2022.151254 · Cited by 21
Prommer, E. (2017) · Palliative Care Research and Treatment · doi:10.1177/1178224217726336 · Cited by 15
Takahashi, S., Matsumoto, K., Ohba, K., Nakano, Y., Miyazawa, Y., & Kawaguchi, T. (2023) · Cancer Management and Research · doi:10.2147/cmar.s417238 · Cited by 17
Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
de Barros, C. T., Rios, A. C., Alves, T., Batain, F., Crescencio, K., Lopes, L. J., Zielińska, A., Severino, P. B., Mazzola, P. G., Souto, E. B., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175974 · Cited by 17
Therapeutic effects of androgens for cachexia
Giovanelli, L., & Quinton, R. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101598 · Cited by 15
Rezaei, S., de Oliveira, L. C., Ghanavati, M., Shadnoush, M., Akbari, M. E., Akbari, A., Hadizadeh, M., Ardehali, S. H., Wakabayashi, H., Elhelali, A., et al. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231189864 · Cited by 13
Nagata, M., Ito, H., Yokose, T., Tokushige, A., Ueda, S., & Nakayama, H. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.16 · Cited by 11
Drugs of Muscle Wasting and Their Therapeutic Targets
Sakuma, K., & Yamaguchi, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_21 · Cited by 14
Currow, D. C., & Skipworth, R. J. E. (2017) · Future Oncology · doi:10.2217/fon-2017-0141 · Cited by 10
Endocrinological aspects of sarcopenic obesity
Minnetti, M., Poggiogalle, E., Frigerio, F., Piciocchi, C., Pierantozzi, G., Vincenzo, O. D., Pinto, A., Gianfrilli, D., Isidori, A. M., Migliaccio, S., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2626085 · Cited by 14
Role of Complementary and Alternative Medicine in the Management of Cancer Cachexia
Shankar, A., Saini, D., Roy, S., Bharati, S. J., Mishra, S., & Singh, P. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon-2149 · Cited by 9
Drugs for the Treatment of Muscle Atrophy
Chen, L., Zhang, H., Chi, M., Yang, Q., & Guo, C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93503 · Cited by 12
THE GHRELIN SYSTEM; BEYOND THE ROLE IN ENERGY HOMEOSTASIS
Šaranac, L., & Gucev, Z. S. (2017) · Facta Universitatis Series Medicine and Biology · doi:10.22190/fumb170118002s · Cited by 5
Song, Z., Chang, H., Han, N., Liu, Z., Wang, Z., Gao, H., & Yin, J. (2017) · RSC Advances · doi:10.1039/c7ra06312a · Cited by 5
Cachexia and anorexia in cancer; a systematic review
Darakhshandeh, A., & Momenzadeh, M. (2020) · Immunopathologia Persa · doi:10.34172/ipp.2021.20 · Cited by 4
Tsurui, T., Hamada, K., Mura, E., Suzuki, R., Iriguchi, N., Ishiguro, T., Hirasawa, Y., Ohkuma, R., Shimokawa, M., Ariizumi, H., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1499650 · Cited by 2
Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine
Hesketh, S. J. (2024) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2024.01.006 · Cited by 3
Anabolic and Anticatabolic Agents in Burns
Vinaik, R., Gus, E. I., & Jeschke, M. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-18940-2_22 · Cited by 2
Marzetti, E., Picca, A., Tummolo, A. M., & Calvani, R. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch99 · Cited by 2
Palliativmedizin: Grundlagen und Symptommanagement
Masel, E. K., & Watzke, H. (2017) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-017-0087-3 · Cited by 1
van Krimpen, S. J., Simons, S. O., Schols, A. M. W. J., LANGEN, R. C. J., & Gosker, H. R. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2620144 · Cited by 2
Der mangelernährte Patient auf der Intensivstation
Bone, H.-G., Sandfeld, C., & Kleynmans, F. (2018) · Intensivmedizin up2date · doi:10.1055/s-0043-122860 · Cited by 1
Background and Management of Muscular Atrophy
Cseri, J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90959 · Cited by 2
Ghrelin and LEAP2: Subtle Players in Cachexia, Essential for the Bigger Picture
Lockie, S. H., & Hagg, A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf093 · Cited by 1
Pharmacological Intervention for Sarcopenia in Chronic Kidney Disease
Sakuma, K., & Yamaguchi, A. (2020) · Springer eBooks · doi:10.1007/978-981-15-2365-6_11
Colorectal Cancer Survivorship: Steps towards integrative oncology and patient-centered cancer care
Derksen, H. W. G. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/128
The role of novel antisense long non-coding RNA, GHRLOS, in prostate and endometrial cancer
Shah, E. T. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.213106
Advances in the diagnosis and treatment of patients with cancer cachexia
Zhou, T., & Yu, S. (2018) · Oncology and Translational Medicine · doi:10.1007/s10330-018-0279-9
Li, N., Zhang, R., Deng, X., Gu, X., Wang, J., Xu, Q., Zhang, X., Guo, X., & Liu, X. (2024) · Discover Medicine · doi:10.1007/s44337-024-00016-8 · Cited by 1
Zamanian, N., Mohajerani, A., Barkhordar, M., Rahimlou, M., Khosroshahi, R. A., Talebi, S., Azari, M., Soleimani, A., & Mohammadi-Kangarani, H. (2026) · Nutrition and Cancer · doi:10.1080/01635581.2026.2652000 · Cited by 1
Metadata
- Authors
- Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z.
- Affiliations
- Nanjing University of Chinese Medicine (CN)
- Corresponding author
- Zhao, Zhiqiang
- Venue
- Supportive Care in Cancer
- Published
- 2017-01-10
- Volume
- 25
- Issue
- 5
- Pages
- 1651-1659
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2569392536
- Cited by
- 52
- References
- 32
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 10 · 2017: 8
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81373608)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- cancer anorexia-cachexia syndrome, lean body mass, body weight, grip strength, insulin-like growth factor I, IGF binding protein-3, adverse events, quality of life, growth hormone secretagogues, placebo comparison, heterogeneity of results, quality of evidence
- MeSH terms
- Anorexia, Cachexia, Female, Humans, Hydrazines, Neoplasms, Oligopeptides, Quality of Life, Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.